GD2-targeted CAR-T cells / Sinobioway - LARVOL DELTA

GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. (PubMed, N Engl J Med) - P1/2 | "The use of GD2-CART01 was feasible and safe in treating high-risk neuroblastoma. Treatment-related toxic effects developed, and the activation of the suicide gene controlled side effects. GD2-CART01 may have a sustained antitumor effect. (Funded by the Italian Medicines Agency and others; ClinicalTrials.gov number, NCT03373097.)."

Journal • CNS Tumor • Neuroblastoma • Neuroendocrine Tumor • Oncology • Solid Tumor

The safety and efficacy of GD2-targeted CAR-T cells in patients with neuroblastoma: a systematic review and meta-analysis. (PubMed, Eur J Med Res) - "CAR-T-cell therapy targeting the GD2 antigen is promising for treating NB. However, its efficacy is moderate, and treatment can lead to hematologic toxicities such as anemia, neutropenia, and thrombocytopenia, which require careful monitoring."

Journal • Retrospective data • Review • Hematological Disorders • Neuroblastoma • Neutropenia • Oncology • Pediatrics • Solid Tumor • Thrombocytopenia

GD2-targeted CAR T cell therapy for childhood solid tumours (EACR 2024) - No abstract available

CAR T-Cell Therapy • Clinical • Oncology • Solid Tumor

Priming of the glioblastoma tumour microenvironment via copper chelation to enhance the efficacy of immunotherapies (AACR 2024) - "In an immunocompetent murine glioblastoma model, combination therapy with GD2-targeted CAR-T cells and TETA effectively slowed tumor growth, demonstrating enhanced efficacy...Our findings suggest that copper chelation, with agents like TETA, can be repurposed as a viable anticancer therapy when combined with immunotherapies. This study provides a compelling rationale for further pre-clinical validation, offering a potential breakthrough in the quest for effective glioblastoma treatments."

Clinical • IO biomarker • Tumor microenvironment • Brain Cancer • CNS Tumor • Glioblastoma • Hematological Malignancies • Oncology • Solid Tumor • PD-L1

AUTO6NG: Next generation GD2-targeting CAR T-cell therapy with improved persistence and insensitivity to TGFβ and checkpoint inhibition for relapsed/refractory neuroblastoma (SITC 2019) - P1; "The AUTO6NG product consists of 3 distinct populations of GD2-targeted CAR T-cells, produced by dual transduction of T-cells with two separate retroviral vectors... These results demonstrate the feasibility, safety, and efficacy of AUTO6NG T-cells. The addition of IL7R_CCR, dnTGFβRII and dSHP2 modules to the AUTO6NG product augment its functions by extending T-cell persistence and rendering modified T-cells resistant to TGFβ- and PD1/PDL1-driven immune inhibition."

CAR T-Cell Therapy • Checkpoint inhibition • IO Biomarker • PD(L)-1 Biomarker

Chimeric Antigen Receptor 4SCAR-GD2-Modified T Cells Targeting High-Risk and Recurrent Neuroblastoma: A Phase II Multi-Center Trial in China (ASH 2017) - P2,P1/2; "Before CART infusion, patients received cyclophosphamide and fludarabine conditioning. This multicenter trial demonstrates that the 4SCAR-GD2 T cells are safe and effective for treating high-risk stage IV NB children. The correlations of GD2 expression in tumor, CART kinetics in blood and treatment responses could not be statistically established, suggesting a vast disease heterogeneity. Important therapeutic correlates require a large patient cohort and long-term follow-ups to elucidate."

Clinical • P2 data • Biosimilar • Dermatology • Hematological Malignancies • Immunology • Neuroendocrine Tumor • Pain

[VIRTUAL] AUTO6NG overcomes immune suppressive mechanisms in the TME and demonstrate preclinical anti-tumor activity in GD2-expressing solid tumors (AACR-II 2020) - "Immune-checkpoint blockade therapies has had impressive results in the clinic and are approved in multiple cancer indications. These CAR-T cells also demonstrated enhanced tumor infiltration and anti-tumor activity in vivo in xenografts mouse models. Our findings suggest that GD2 targeted CAR-T cell therapy is a viable novel approach for the treatment of multiple solid tumors indications."

IO Biomarker • Preclinical • Lung Cancer • Melanoma • Neuroblastoma • Oncology • Small Cell Lung Cancer • Thoracic Cancer

Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M diffuse midline gliomas. (PubMed, Nat Med) - "Given the precarious neuroanatomical location of midline gliomas, careful monitoring and aggressive neurointensive care management will be required for human translation. With a cautious multidisciplinary clinical approach, GD2-targeted CAR T cell therapy for H3-K27M diffuse gliomas of pons, thalamus and spinal cord could prove transformative for these lethal childhood cancers."

CAR T-Cell Therapy • Clinical • Journal